:: Volume 17, Issue 2 (Summer 2015) ::
EBNESINA 2015, 17(2): 4-11 Back to browse issues page
Anti-tumor effects of a new triazene compound: A laboratory study
S Amirpour Asl , M Nabiuni , Z Yazdanian , MK Rofouei , M Mahdavi , A Khoshvagti , L Karimzadeh
Faculty of Biological Science, Kharazmi University, Tehran, Iran , Saber.amirpour@gmail.com
Abstract:   (4732 Views)

Background: Triazene compounds have many applications in various fields such as anticancer drugs. In this study, we aimed to find out anti-cancerous effects of 1-(3, 5-dichlorophenyl)-3-(2-ethoxyphenyl) triazene on 4T1 cell line and induced breast cancer in mice. Materials and methods: 4T1 cell line was cultured and then treated for 24h with different concentrations of new triazene compound. Cell viability was assessed by MTT assay. For tumor induction, we used 7-8 weeks old Balb/C mice. Then 4T1 cells were injected subcutaneously with appropriate concentration. When tumor observed, mice were randomly assigned to groups. Mice were treated with different concentration of new triazene compound. Tumor sizes in each group were compared before and after the treatment. Expression of Bax gene was analyzed by RT-PCR. Results: MTT assay results shows that IC50 for new triazene compound on 4T1 cell line in 24h was 30µ Mol. Also analysis of tumor size shows a significant reduction at triazene treated groups compared with the control group. RT-PCR result shows increase in Bax gene expression at triazene treated groups compared with the control group. Conclusion: New triazene compound could reduce 4T1 cell viability invitro and also could reduce tumor size invivo. Also, it could induce apoptosis in tumor tissues by increase in Bax gene expression.

Keywords: Breast Cancer, Diazoamino Compounds, Tumor Cell Lines, Bax Protein
Full-Text [PDF 547 kb]   (1690 Downloads)    
Type of Study: Original | Subject: Aerospace Medicine
Received: 2015/10/4 | Accepted: 2015/10/4 | Published: 2015/10/4


XML   Persian Abstract   Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 17, Issue 2 (Summer 2015) Back to browse issues page